Albertini, Mark R.
Yang, Richard K.
Ranheim, Erik A.
Hank, Jacquelyn A.
Zuleger, Cindy L.
Weber, Sharon
Neuman, Heather
Hartig, Greg
Weigel, Tracey
Mahvi, David
Henry, Mary Beth
Quale, Renae
McFarland, Thomas
Gan, Jacek
Carmichael, Lakeesha
Kim, KyungMann
Loibner, Hans
Gillies, Stephen D.
Sondel, Paul M.
Funding for this research was provided by:
National Cancer Institute (R01 CA032685, R01 CA087025, R35 CA166105, P30 CA014520)
National Center for Advancing Translational Sciences (UL1TR000427)
Article History
Received: 10 May 2018
Accepted: 30 July 2018
First Online: 3 August 2018
Compliance with ethical standards
:
: The authors have the following financial or other conflicts of interests to disclose related to this publication: Dr. Hans Loibner is CEO for Apeiron Biologics AG, and Apeiron Biologics AG has ownership of the hu18.18-IL2 immunocytokine used in this study. The remaining authors reported no financial or other conflicts of interest to disclose related to this publication.
: The UW Human Subjects Committee and the FDA approved the study (ClinicalTrials.gov identifier: NCT00590824; IND 12220). All procedures performed in studies involving human participants were in accordance with ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Written informed consent was obtained from all individual participants included in the study and all individual participants registered with the Biostatistics Registration Desk prior to treatment.